Filtered By:
Cancer: Breast Cancer

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 2131 results found since Jan 2013.

Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1
CONCLUSION: Our findings suggest for the first time that the 5-HT7 receptor promotes FOXM1, eEF2K and cyclin D1 signaling to support TNBC cell proliferation; thus, inhibition of 5-HT7 receptor/FOXM1 signaling may be used as a potential therapeutic strategy for targeting TNBC. 5-HT induces cell proliferation of TNBC cells through 5-HT7 receptor signaling. Also, genetic and pharmacological inhibition of 5-HT7 by RNAi (siRNA) and metergoline HTR7 antagonist, respectively inhibits FOXM1 oncogenic transcription factor and suppresses TNBC cell proliferation.PMID:36006564 | DOI:10.1007/s12282-022-01391-9
Source: Breast Cancer - August 25, 2022 Category: Cancer & Oncology Authors: Venhar C ınar Zuhal Hamurcu Ahsen Guler Nursultan Nurdinov Bulent Ozpolat Source Type: research

GSE209693 Effect of AKTIP depletion in breast cancer cells
Contributor : Lydia W CheungSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCopy number loss of AKTIP gene is frequently observed in breast cancer particularly luminal breast cancer. To determine the alterations in transcriptome upon AKTIP loss in luminal breast cancer cell line MCF7 and triple negative breast cancer cell line SKBR3, RNAseq of cells transfected with AKTIP siRNA was performed.
Source: GEO: Gene Expression Omnibus - August 19, 2022 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Glycoproteomics Identifies Plexin-B3 as a Targetable Cell Surface Protein Required for the Growth and Invasion of Triple-Negative Breast Cancer Cells
J Proteome Res. 2022 Aug 18. doi: 10.1021/acs.jproteome.2c00332. Online ahead of print.ABSTRACTDriven by the lack of targeted therapies, triple-negative breast cancers (TNBCs) have the worst overall survival of all breast cancer subtypes. Considering that cell surface proteins are favorable drug targets and are predominantly glycosylated, glycoproteome profiling has significant potential to facilitate the identification of much-needed drug targets for TNBCs. Here, we performed N-glycoproteomics on six TNBCs and five normal control (NC) cell lines using hydrazide-based enrichment. Quantitative proteomics and integrative dat...
Source: Cancer Control - August 18, 2022 Category: Cancer & Oncology Authors: Laura Kuhlmann Meinusha Govindarajan Salvador Mejia-Guerrero Vladimir Ignatchenko Lydia Y Liu Barbara T Gr ünwald Jennifer Cruickshank Hal Berman Rama Khokha Thomas Kislinger Source Type: research

PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations
We examined three HER2-positive, ER-negative breast cancer cell lines to determine the efficacy of a novel alpha isoform-specific PI3K inhibitor in combination with trastuzumab. The results indicated that this combination was effective in PIK3CA-mutant or PTEN-deficient breast cancer cells by inducing apoptosis and inhibiting the expression of downstream proteins. PTEN loss by siRNA modulation in parental HER2-positive cancer cells with PI3K signaling pathway alterations could not confer resistance to alpelisib or GDC-0077 plus trastuzumab. We selected the CK-MB-1 cell line without alterations in the PI3K pathway to demons...
Source: Cell Research - August 15, 2022 Category: Cytology Authors: Wei-Pang Chung Wei-Lun Huang Chun-Hui Lee Hui-Ping Hsu Wan-Ling Huang You-Yu Liu Wu-Chou Su Source Type: research

Efp promotes growth of triple-negative breast cancer cells
Biochem Biophys Res Commun. 2022 Jul 30;624:81-88. doi: 10.1016/j.bbrc.2022.07.071. Online ahead of print.ABSTRACTTriple-negative breast cancer (TNBC) is characterized by its high ability of invasiveness and metastasis, namely lacking expression of estrogen receptor (ER), progesterone receptor, and HER2. We previously demonstrated that estrogen responsive finger protein (Efp) plays a tumor-promotive role in ER-positive breast cancer, yet it remains to be addressed whether Efp contributes to TNBC pathophysiology. We here found that Efp mRNA and protein were abundantly expressed in TNBC patient-derived cells and MDA-MB-231 c...
Source: Cell Research - August 8, 2022 Category: Cytology Authors: Wataru Sato Kazuhiro Ikeda Noriko Gotoh Satoshi Inoue Kuniko Horie Source Type: research

Preliminary evaluation of a small interfering RNA molecular probe targeting murine double minute 2 in breast cancer
Conclusion The [99mTc]HYNIC-siRNA 1489 was taken up by the tumor, which had a high level of MDM2. The probe exhibited a sufficient retention time in the tumor. This probe may be an effective strategy for evaluating MDM2 expression and achieving early diagnosis in breast cancer.
Source: Nuclear Medicine Communications - July 21, 2022 Category: Nuclear Medicine Tags: Original Articles Source Type: research

ANKHD1 contributes to the malignant phenotype of triple-negative breast cancer cells
Cell Biol Int. 2022 Jul 16. doi: 10.1002/cbin.11844. Online ahead of print.ABSTRACTAnkyrin repeat and KH domain-containing protein 1, ANKHD1, has been identified as a regulator of signaling pathways and cellular processes of relevance in carcinogenesis. However, the role of ANKHD1 in breast cancer remains unclear. The aim of the present study was to characterize the expression pattern and involvement of ANKHD1 in the malignant phenotype of breast cancer cell lines and to investigate the clinical relevance of ANKHD1 in a breast cancer context. Gene and protein expressions were assessed in the cell lines by quantitative reve...
Source: Cell Biology International - July 17, 2022 Category: Cytology Authors: Bruna O de Almeida Larissa C de Almeida Leticia V Costa-Lotufo Jo ão A Machado-Neto Source Type: research